Intensified Therapy with Inhaled Corticosteroids and Long-Acting β-Agonists at the Onset of Upper Respiratory Tract Infection to Prevent Chronic Obstructive Pulmonary Disease Exacerbations. A Multicenter, Randomized, Double-Blind, Placebo-controlled Trial.

Am J Respir Crit Care Med 2018 05;197(9):1136-1146

1 Clinic of Respiratory Medicine and Pulmonary Cell Research, and.

Rationale: The efficacy of intensified combination therapy with inhaled corticosteroids (ICS) and long-acting β-agonists (LABA) at the onset of upper respiratory tract infection (URTI) symptoms in chronic obstructive pulmonary disease (COPD) is unknown.

Objectives: To evaluate whether intensified combination therapy with ICS/LABA, at the onset of URTI symptoms, decreases the incidence of COPD exacerbation occurring within 21 days of the URTI.

Methods: A total of 450 patients with stable, moderate to very severe COPD, were included in this investigator-initiated and -driven, double-blind, randomized, placebo-controlled study. At inclusion, patients were assigned to open-labeled low-maintenance dose ICS/LABA. Each patient was randomized either to intensified-dose ICS/LABA or placebo and instructed to start using this medication only in case of a URTI, at the onset of symptoms, twice daily, for 10 days.

Measurements And Main Results: The incidence of any exacerbation following a URTI was not significantly decreased in the ICS/LABA group, as compared with placebo (14.6% vs. 16.2%; hazard ratio, 0.77; 95% confidence interval, 0.46-1.33; P = 0.321) but the risk of severe exacerbation was decreased by 72% (hazard ratio, 0.28; 95% confidence interval, 0.11-0.74%; P = 0.010). In the stratified analysis, effect size was modified by disease severity, fractional exhaled nitric oxide, and the body mass index-airflow obstruction-dyspnea, and exercise score. Compared with the stable period, evidence of at least one virus was significantly more common at URTI, 10 days after URTI, and at exacerbation.

Conclusions: Intensified combination therapy with ICS/LABA for 10 days at URTI onset did not decrease the incidence of any COPD exacerbation but prevented severe exacerbation. Patients with more severe disease had a significant risk reduction for any exacerbation. Clinical trial registered with www.isrctn.com (ISRCTN45572998).

Download full-text PDF

Source
http://dx.doi.org/10.1164/rccm.201709-1807OCDOI Listing
May 2018
23 Reads

Publication Analysis

Top Keywords

combination therapy
12
intensified combination
12
chronic obstructive
8
urti onset
8
95% confidence
8
respiratory tract
8
tract infection
8
obstructive pulmonary
8
copd exacerbation
8
hazard ratio
8
days urti
8
pulmonary disease
8
incidence copd
8
upper respiratory
8
confidence interval
8
urti symptoms
8
long-acting β-agonists
8
inhaled corticosteroids
8
therapy ics/laba
8
therapy inhaled
8

Altmetric Statistics

References

(Supplied by CrossRef)

Hoyert D et al.
Natl Vital Stat Rep 2005

Similar Publications